Back to results
US 2012/0269773 A1Published application
Recombinant adenoviruses encoding the specific iodine transporter (nis)
AssigneeAventis Pharma S.A.
InventorsMichel PERRICAUDET, Martin SCHLUMBERGER, Patrice YEH, Anne BOLAND-AUGE
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of gene therapy and the treatment of tumors.
Claims7
A method for treating and/or inhibiting the growth of tumors, comprising the administration of an effective quantity of a defective recombinant adenovirus, wherein the defective recombinant adenovirus comprises
- i) a promoter allowing expression in tumor cells wherein the promoter is selected from the group consisting of ElA, MLP, CMV and RSV-LTR, MT-1, SV40;
- ii) at least one DNA sequence encoding the specific human iodine transporter (Naf/I-Symporter) NIS comprising at least a deletion of all or part of the El region and −a deletion of all or part of the El region;
- and
- iii) at least one gene encoding a polypeptide involved in a peroxidase system such as the gene for glucose oxidase or for thyroperoxidase.
1 more element
A method for treating and/or inhibiting the growth of tumors, comprising the administration of a pharmaceutical composition comprising defective recombinant adenoviruses that comprise:
- i) a promoter allowing expression in tumor cells wherein the promoter is selected from the group consisting of ElA, MLP, CMV and RSV-LTR, MT-1, SV40;
- ii) at least one DNA sequence encoding the specific human iodine transporter (Naf/I-Symporter) NIS comprising at least a deletion of all or part of the El region and −a deletion of all or part of the El region;
- and
- iii) at least one gene encoding a polypeptide involved in a peroxidase system such as the gene for glucose oxidase or for thyroperoxidase.
1 more element
Dependencies are inferred from the claim text.